CORRECTION: Corebridge Financial Ticker Is CRBG
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/9/2024 | $35.00 | Buy | TD Cowen | |
| 9/5/2024 | $33.00 | Equal Weight | Barclays | |
| 7/11/2023 | $18.00 → $19.00 | Neutral | Citigroup | |
| 6/29/2023 | $22.00 | Buy | UBS | |
| 4/11/2023 | $24.00 → $18.00 | Neutral | Citigroup | |
| 4/4/2023 | $25.00 → $23.00 | Neutral → Buy | Goldman |
8-A12B - Corebridge Financial, Inc. (0001889539) (Filer)
8-K - Corebridge Financial, Inc. (0001889539) (Filer)
10-Q - Chain Bridge I (0001845149) (Filer)
SC 13G/A - Chain Bridge I (0001845149) (Subject)
SC 13G/A - Chain Bridge I (0001845149) (Subject)
SC 13G/A - Chain Bridge I (0001845149) (Subject)
Corebridge Financial, Inc. (NYSE:CRBG) today announced that the previously announced secondary offering by American International Group, Inc. (NYSE:AIG) of common stock of Corebridge Financial has priced at $31.20 per share. The offering is expected to close on November 12, 2024, subject to customary closing conditions. AIG, as the selling stockholder, has offered 30 million existing shares of common stock (out of approximately 568 million total shares of common stock outstanding) of Corebridge Financial, corresponding to approximately $936 million of gross proceeds. AIG has also granted a 30-day option to the underwriters to purchase up to an additional 4.5 million shares. All of the net
Corebridge Financial, Inc. (NYSE:CRBG) today announced the launch of a secondary offering of its common stock by American International Group, Inc. (NYSE:AIG). AIG, as the selling stockholder, is offering 30 million existing shares of common stock (out of approximately 568 million total shares of common stock outstanding) of Corebridge Financial and has granted a 30-day option to the underwriters to purchase up to an additional 4.5 million shares. All of the net proceeds from the offering will go to AIG. The last reported per share sale price of Corebridge Financial common stock on November 6, 2024 was $33.37. J.P. Morgan and Morgan Stanley are acting as the underwriters for the offering.
Net loss of $1.2 billion, or $2.02 per share, largely a result of realized losses primarily driven by the Fortitude Re funds withheld embedded derivative Adjusted after-tax operating income1 of $810 million and operating EPS1 of $1.38 per share Premiums and deposits1 of $9.6 billion Aggregate core sources of income2 increased 4% over the prior year quarter with growth across base spread income,2 fee income2 and underwriting margin2,3 Holding company liquidity of $2.0 billion Returned $848 million to shareholders, including $715 million of share repurchases Corebridge Financial, Inc. ("Corebridge" or the "Company") (NYSE:CRBG) today reported financial results for the third quart
American International Group, Inc. (NYSE:AIG) today announced that Patricia (Trish) Walsh will join AIG as Executive Vice President and General Counsel, effective December 1, 2023. Ms. Walsh will report to Peter Zaffino, AIG Chairman & Chief Executive Officer, and serve on AIG's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928917765/en/Patricia J. Walsh (Photo: Business Wire) As General Counsel, Ms. Walsh will be responsible for AIG's legal, compliance, and regulatory functions, in addition to leading government affairs for the company. Rose Marie Glazer will remain Interim General Counsel until M
Net loss of $1.2 billion, or $2.02 per share, largely a result of realized losses primarily driven by the Fortitude Re funds withheld embedded derivative Adjusted after-tax operating income1 of $810 million and operating EPS1 of $1.38 per share Premiums and deposits1 of $9.6 billion Aggregate core sources of income2 increased 4% over the prior year quarter with growth across base spread income,2 fee income2 and underwriting margin2,3 Holding company liquidity of $2.0 billion Returned $848 million to shareholders, including $715 million of share repurchases Corebridge Financial, Inc. ("Corebridge" or the "Company") (NYSE:CRBG) today reported financial results for the third quart
Corebridge Financial, Inc. (NYSE:CRBG) today announced that it will report third quarter 2024 financial results after the market closes on Monday, November 4, 2024. Corebridge earnings materials will be available in the Investors section of corebridgefinancial.com. Corebridge will host a conference call at 11:00 a.m. EST on Tuesday, November 5, 2024, to review these results. The webcast can be accessed in the Investors section of corebridgefinancial.com, and a replay will be available shortly after the event. About Corebridge Financial Corebridge Financial, Inc. makes it possible for more people to take action in their financial lives. With more than $390 billion in assets under manageme
Corebridge MarketLock Annuity features an exclusive new accumulation strategy, along with many of the most popular RILA investment options in the market Corebridge Financial today announced the launch of Corebridge MarketLock® Annuity, a registered index-linked annuity (RILA) issued by its subsidiary American General Life Insurance Company. MarketLock features a powerful accumulation strategy exclusive to Corebridge, as well as many of the most popular RILA investment strategies sought by financial professionals and their clients. All the investment strategies in the Corebridge RILA offer growth potential and a level of downside protection. With its new RILA, Corebridge has added to its e
4 - Corebridge Financial, Inc. (0001889539) (Reporting)
4 - Corebridge Financial, Inc. (0001889539) (Reporting)
4 - Corebridge Financial, Inc. (0001889539) (Issuer)
4 - Corebridge Financial, Inc. (0001889539) (Issuer)
4 - Corebridge Financial, Inc. (0001889539) (Reporting)
Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and short-term debt, which will convert to preferred stock upon the deal’s closure, slated for the fourth quarter of 2024. Phytanix Bio’s Strategic Acquisition Overview Phytanix Bio, a company founded by former GW Pharmaceuticals leaders, holds exclusive intellectual property that has been central to the creation of FDA-approved cannabinoid-based medicines like Sativex and Epidiolex. With the ac
Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "PHYX." Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines. The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close
Exchange Offer for up to $500 million of its 6.050% Senior Notes due 2033Corebridge Financial, Inc. (the "Company") announced today that effective at 10:00 a.m. EDT on July 15, 2024, the U.S. Securities and Exchange Commission declared effective its previously filed Registration Statement on Form S-4 for the exchange of up to $500 million aggregate principal amount of its outstanding 6.050% Senior Notes due 2033 (the "Old Notes") for a like principal amount of its 6.050% Senior Notes due 2033 (the "New Notes"), which have been registered under the Securities Act of 1933, as amended.Accordingly, the Company announced that, effective July 15, 2024, it has launched its offer to exchange the Old
TD Cowen initiated coverage of Corebridge Financial with a rating of Buy and set a new price target of $35.00
Barclays initiated coverage of Corebridge Financial with a rating of Equal Weight and set a new price target of $33.00
Citigroup resumed coverage of Corebridge Financial with a rating of Neutral and set a new price target of $19.00 from $18.00 previously
